Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

Seaver Autism Center, Mount Sinai Medical Center, New York

New York State Institute for Basic Research in Developmental Disabilities, Staten Island

Suburban Research Associates/Elwyn Genetics, Media

Kennedy Krieger Institute, Baltimore

Duke Clinical Research Unit, Durham

Greenwood Genetics Center, Greenwood

Emory University School of Medicine, Decatur

Lake Mary Pediatrics, Orange City

University of Miami, Mailman Center for Child Development, Miami

Vanderbilt Kennedy Center, Nashville

Akron Children's Hospital, Akron

Cincinnati Children's Hospital, Cincinnati

Children's Hospital of Michigan, Detriot

Rush University Medical Center, Chicago

University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders, Columbia

Kansas University Clinical Research Center, Fairway

University of Oklahoma, Physician's Child Study Center, Oklahoma City

Childrens Medical Center Dallas, Dallas

Texas Children's Hospital, Houston

Red Oaks Psychiatry Associates, P.A., Houston

Road Runner Research, San Antonio

University of Colorado Denver, Children's Hospital, Aurora

Southwest Autism Research & Resource Center, Phoenix

Miller Children's Hospital, Long Beach

Psychiatric Centers at San Diego, San Diego

University of California-Davis, M.I.N.D. Institute, Sacramento

Seattle Children's Hospital, Seattle

University of Massachusetts, Worcester